Jagsonpal Pharmaceuticals Limited has announced Q1 FY25 revenues of Rs. 61.4 crores, a 41% growth over Q4 FY24 and Operating EBITDA at Rs. 12.7 crores, margins at 20.6% for the quarter ended June 2024.
Jagsonpal Pharmaceuticals Limited announced the financial results for Q3 FY23 quarter ended December 31st, 2022 revenues grew by 11.6% to Rs. 60.1 crore.